Timber Pharmaceuticals Inc. [AMEX: TMBR] closed the trading session at $1.52 on 10/21/20. The day’s price range saw the stock hit a low of $1.10, while the highest price level was $1.63. The company report on September 15, 2020 that Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for BPX-01 and BPX-04.
– Formal notice confirms intent to grant patent for pharmaceutical tetracycline compositions for dermatological use -.
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.
via NEWMEDIAWIRE — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that it has received a formal notice of allowance from the U.S. Patent and Trademark Office (USPTO) for the Company’s patent application covering its pharmaceutical tetracycline (including minocycline) compositions for dermatological use (U.S. Patent Application No.: 16/514,459).
The stocks have a year to date performance of -70.13 percent and weekly performance of 43.40 percent. The stock has been moved at -59.07 percent over the last six months. The stock has performed 61.50 percent around the most recent 30 days and changed -27.96 percent over the most recent 3-months.
If compared to the average trading volume of 618.09K shares, TMBR reached to a volume of 6856281 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Timber Pharmaceuticals Inc. [TMBR]:
The Average True Range (ATR) for Timber Pharmaceuticals Inc. is set at 0.11, with the Price to Sales ratio for TMBR stock in the period of the last 12 months amounting to 51.97.
TMBR stock trade performance evaluation
Timber Pharmaceuticals Inc. [TMBR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 43.40. With this latest performance, TMBR shares gained by 61.50% in over the last four-week period, additionally sinking by -59.07% over the last 6 months – not to mention a drop of -61.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TMBR stock in for the last two-week period is set at 79.99, with the RSI for the last a single of trading hit 87.42, and the three-weeks RSI is set at 66.74 for Timber Pharmaceuticals Inc. [TMBR]. The present Moving Average for the last 50 days of trading for this stock 1.1802, while it was recorded at 1.1600 for the last single week of trading, and 3.1684 for the last 200 days.
Timber Pharmaceuticals Inc. [TMBR]: An insightful look at the core fundamentals
Timber Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 10.50.
Earnings per share (EPS) analysis for Timber Pharmaceuticals Inc. [TMBR] stock
With the latest financial reports released by the company, Timber Pharmaceuticals Inc. posted -2.64/share EPS, while the average EPS was predicted by analysts to be reported at -4.02/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 34.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TMBR.
Timber Pharmaceuticals Inc. [TMBR]: Insider Ownership positions
There are presently around $0 million, or 11.30% of TMBR stock, in the hands of institutional investors. The top three institutional holders of TMBR stocks are: DEUTSCHE BANK AG with ownership of 53,678, which is approximately New of the company’s market cap and around 45.20% of the total institutional ownership; UBS GROUP AG, holding 4,683 shares of the stock with an approximate value of $7000.0 in TMBR stocks shares; and MORGAN STANLEY, currently with $5000.0 in TMBR stock with ownership of nearly New of the company’s market capitalization.
6 institutional holders increased their position in Timber Pharmaceuticals Inc. [AMEX:TMBR] by around 58,543 shares. Additionally, 8 investors decreased positions by around 25,977 shares, while 0 investors held positions by with 22,131 shares. The mentioned changes placed institutional holdings at 62,389 shares, according to the latest SEC report filing. TMBR stock had 3 new institutional investments in for a total of 56,753 shares, while 7 institutional investors sold positions of 25,975 shares during the same period.